Answers are grounded in this paper and cite their sources.
FGFR3-TACC3 rearrangements occur in a subset of patients with lung adenocarcinoma. Such patients should be considered for clinical trials featuring FGFR inhibitors.
No takes yet. Share an insight, caveat, or question.
Capelletti et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: